Medicare Plans’ Formulary Restrictions Will Get More Scrutiny In 2010 Bids – CMS
This article was originally published in The Pink Sheet Daily
The agency proposes that next year’s Part D bids report new drug utilization requirements in a clear and consistent way to make it easier to assess policy compliance.
You may also be interested in...
National stand-alone Medicare drug plans co-sponsored by UnitedHealth and AARP will impose new formulary restrictions in major drug categories including cholesterol treatments, proton pump inhibitors and osteoporosis therapies in 2009 to help control costs
CMS is aiming to make Medicare Part D formulary prior authorization practices more clear and consistent by proposing new requirements for drug plans in its draft "call letter" to prospective plan sponsors for the 2009 benefit year
In the report accompanying FY 2023 HHS appropriations legislation, the House committee also addresses biosimilar uptake in Part D, Medicare dispensing fees for oral COVID-19 drugs and NIH grants for expanded access to investigational ALS drugs.